Neoadjuvant tislelizumab plus pazopanib in renal cell carcinoma with venous tumour thrombus: A retrospective study
The neoadjuvant combination of tislelizumab and pazopanib effectively reduced tumour size and thrombus length, narrowing the surgical scope and potentially leading to better postoperative outcomes.
Authors
- Baihetiya Azhati (ORCID: https://orcid.org/0009-0006-4874-6129)
- Huixiang Chen (ORCID: https://orcid.org/0000-0002-4260-9899)
- Diliyaer Dilixiati (ORCID: https://orcid.org/0000-0002-7603-9126)
- Hongliang Li (ORCID: https://orcid.org/0000-0002-9821-0297)
- Shiping Xie (ORCID: https://orcid.org/0000-0002-9947-2440)
- Naifeisha Aihemaiti
- Gulizhaer Abulimiti
Institutions
- Xinjiang Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- First Affiliated Hospital of Xinjiang Medical University (CN)
Publication Details
- Journal
- BJUI Compass
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1002/bco2.70095
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00